Stevanato Group (STVN) AI Stock Analysis

• Market Cap: $6.25B
• Dividend Yield: 0.27%
• Average Volume (3M): 319.58K
• Price to Earnings (P/E): 40.3
• Beta (1Y): 0.72
• Revenue Growth: 9.19%
• EPS Growth: 23.06%
• Country: US
• Employees: 5,521
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.16
• Shares Outstanding: 49,604,650
• 10 Day Avg. Volume: 438,358
• 30 Day Avg. Volume: 319,583
• PEG Ratio: -2.23
• Price to Book (P/B): 4.09
• Price to Sales (P/S): 5.20
• P/FCF Ratio: -36.39
• Enterprise Value/Market Cap: 1.19
• Enterprise Value/Revenue: 6.34
• Enterprise Value/Gross Profit: 22.16
• Enterprise Value/Ebitda: 26.56
• 1Y Price Target: $28.00
• Price Target Upside: 22.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.61
• Revenue Forecast (FY): $1.36B

• Rating: 67 Neutral
• Price Target: $25.00 ▲(9.17% Upside)

Stevanato Group's overall stock score is driven by strong financial performance and positive earnings call sentiment, highlighting revenue growth and strategic investments. However, technical indicators suggest bearish momentum, and the stock's valuation appears high, which may limit upside potential.

Positive Factors

Revenue Growth

Consistent revenue growth, driven by demand in core drug containment, indicates strong market position and product adoption.

High-Value Solutions

The shift towards high-value solutions like Nexa syringes enhances margins and strengthens competitive advantage.

Capacity Expansion

Investments in capacity expansion support future growth and meet increasing demand, ensuring long-term operational scalability.

Negative Factors

Engineering Segment Decline

The decline in the Engineering segment highlights challenges in diversifying revenue streams and maintaining segment profitability.

Cash Flow Challenges

Negative free cash flow growth indicates potential liquidity issues, impacting the company's ability to fund operations and investments.

Foreign Currency Headwinds

Currency fluctuations pose a risk to revenue stability, affecting financial performance and complicating international operations.

Stevanato Group Business Overview & Revenue Model

Company Description

Stevanato Group (STVN) is a leading global provider of integrated solutions for the pharmaceutical and biotechnology sectors, specializing in the design and manufacturing of glass primary packaging and drug delivery systems. The company operates in two main segments: Glass & Devices, which includes the production of vials, syringes, and cartridges, and Engineering, which offers a range of services including the development of automated systems for the pharmaceutical industry. Stevanato Group is committed to innovation, quality, and sustainability, providing advanced solutions that support the safe and effective delivery of medications.

How the Company Makes Money

Stevanato Group generates revenue primarily through the sale of its glass packaging products and drug delivery systems to pharmaceutical and biotech companies. Key revenue streams include the manufacturing and sale of vials, syringes, and cartridges, which are critical for the storage and delivery of injectable drugs. Additionally, the company offers engineering services, including the design and implementation of automated systems for drug packaging and delivery, which further contributes to its earnings. Significant partnerships with major pharmaceutical companies enhance its revenue potential, as these collaborations often lead to long-term contracts and increased demand for its products. The company also benefits from a growing global demand for biologics and personalized medicine, which drives the need for innovative packaging solutions.

Stevanato Group Financial Statement Overview

Summary

Stevanato Group demonstrates strong revenue growth and profitability, supported by a solid balance sheet with low leverage. However, cash flow challenges, particularly in free cash flow generation, pose a potential risk. Overall, the company is financially stable but should focus on improving cash flow efficiency.

Income Statement

Stevanato Group shows a steady revenue growth trajectory with a TTM revenue growth rate of 2.21%. The gross profit margin is stable at 28.63%, and the net profit margin is healthy at 12.02%. However, there is a slight decline in margins compared to previous years, indicating potential cost pressures or pricing challenges.

Balance Sheet

The company's balance sheet is strong with a low debt-to-equity ratio of 0.32, indicating prudent financial leverage. Return on equity is solid at 9.95%, reflecting efficient use of equity capital. The equity ratio stands at 59.54%, showcasing a robust capital structure.

Cash Flow

Cash flow analysis reveals challenges, with a significant decline in free cash flow growth at -110.26% TTM. The operating cash flow to net income ratio is moderate at 0.50, suggesting adequate cash generation relative to earnings. However, the free cash flow to net income ratio is low at 0.06, indicating limited free cash flow relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.17B	1.10B	1.09B	983.68M	843.92M	662.04M
Gross Profit	335.13M	302.32M	339.89M	319.80M	265.40M	194.18M
EBITDA	279.53M	247.80M	272.35M	256.40M	226.93M	156.38M
Net Income	140.60M	117.78M	145.63M	142.85M	134.32M	78.51M
Balance Sheet
Total Assets	2.41B	2.33B	2.07B	1.66B	1.42B	967.98M
Cash, Cash Equivalents and Short-Term Investments	113.33M	98.27M	70.35M	256.65M	438.21M	157.12M
Total Debt	450.33M	428.97M	396.59M	218.37M	244.29M	363.01M
Total Liabilities	976.90M	924.43M	938.93M	663.79M	577.18M	657.84M
Stockholders Equity	1.44B	1.40B	1.13B	996.13M	842.07M	310.50M
Cash Flow
Free Cash Flow	-33.72M	-157.79M	-336.72M	-139.81M	20.16M	59.65M
Operating Cash Flow	235.60M	155.78M	105.21M	103.31M	133.34M	155.66M
Investing Cash Flow	-269.60M	-310.21M	-421.22M	-242.95M	-96.43M	-96.09M
Financing Cash Flow	-16.30M	183.22M	158.03M	-44.54M	254.85M	-26.52M

Stevanato Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 22.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Negative. The current price of 22.9 is below the 20-day moving average (MA) of 23.34, below the 50-day MA of 24.66, and below the 200-day MA of 23.25, indicating a bearish trend. The MACD of -0.66 indicates Negative momentum. The RSI at 45.55 is Neutral, neither overbought nor oversold. The STOCH value of 73.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STVN.

Stevanato Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	78 Outperform	$5.18B	44.74	8.30%	―	11.49%	-2.89%
LMAT	75 Outperform	$1.95B	41.90	15.02%	0.96%	13.07%	27.98%
RGEN	68 Neutral	$9.64B	6,660.70	0.08%	―	11.74%	―
STVN	67 Neutral	$6.25B	40.25	9.81%	0.27%	9.19%	23.06%
TFX	60 Neutral	$4.83B	―	-7.90%	1.18%	5.43%	-245.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATR	50 Neutral	$8.12B	19.84	15.80%	1.48%	2.50%	25.05%

Stevanato Group Corporate Events

Stevanato Group Exceeds Q3 Expectations and Advances Key Projects

On November 6, 2025, Stevanato Group held a conference call to discuss its third-quarter financial results, which exceeded expectations due to strong revenue growth and margin expansion. The company reported a 9% increase in revenue year-over-year, driven by a 14% growth in its BDS segment, primarily due to demand in its core drug containment business. Despite facing challenges from foreign currency and tariff costs, Stevanato remains on track to meet its 2025 guidance. The company is advancing its capital investment projects in Fishers and Latina to meet rising market demand, particularly in the biologics sector. Additionally, Stevanato’s commitment to sustainability was recognized with an EcoVadis Silver Medal, placing it in the top 15% of companies assessed globally.

Stevanato Group Achieves 9% Revenue Growth in Q3 2025

Stevanato Group reported a 9% increase in revenue for the third quarter of 2025, reaching €303.2 million, with high-value solutions accounting for a record 49% of total revenue. The company’s Biopharmaceutical and Diagnostic Solutions segment drove this growth, offsetting a decline in the Engineering Segment. The financial results were bolstered by favorable product shipment timing and increased demand for high-performance Nexa® syringes. Despite challenges such as foreign currency impacts and tariff costs, Stevanato Group maintained its fiscal 2025 guidance, highlighting its strategic investments in capacity expansion and innovation to support future growth.

Stevanato Group Discusses Q3 2025 Financial Results Amid Global Challenges

On November 6, 2025, Stevanato Group held an investor conference call to discuss its Q3 2025 financial results. The company is navigating various challenges, including global supply chain issues and geopolitical tensions, while focusing on expanding its capacity to meet customer demand. Despite these hurdles, Stevanato Group remains committed to optimizing its industrial footprint and enhancing its supply chain strategies, which are crucial for maintaining its competitive edge in the healthcare sector.

Stevanato Group Releases Interim Financial Report for September 2025

Stevanato Group released its interim financial report for the three and nine months ending September 30, 2025, highlighting the company’s performance and strategic initiatives. The report provides insights into the company’s efforts to optimize its industrial footprint and enhance supply chain strategies amidst global economic challenges. The company faces risks related to market competition, supply chain disruptions, and geopolitical tensions, which could impact its operations and financial performance.